An interventional study of rTMS Over Contralateral Hemisphere of Premotor Cortex and rTMS Over Ipsilateral Hemisphere of Premotor Cortex in Stroke, sponsored by Emory University. Terminated at 1 site in United States. Open to participants aged 55 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Emory University · Not applicable, Interventional, and Basic science
Study was suspended pending additional funding to continue participant recruitment and was ultimately terminated in 2024.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Stroke by Emory University — 4 open to participants now, 4 under way, none of them phase 3. Stroke · Emory University.
Among the 23 studies in Stroke by Emory University, this one is the 20th largest by enrollment, is one of 2 that started in 2016, is one of 17 with no phase, and was the 11th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →4 of the 23 studies in Stroke by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18–80
Emory University · Sites in United States
Ages 40–90
Emory University · Sites in United States
Ages 40–85
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 32 across the 23 interventional studies. Of the 17 that completed or were terminated, 11 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
2 of the studies in Stroke by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189819Emory UniversityInnovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait | 2027-01-31 |
| NCT07663292Emory UniversityNeuroplastic Changes Due to an Exercise Intervention That Aid in Lower Limb Recovery After Subcortical Stroke | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Stroke by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to determine the effect of repetitive transcranial magnetic stimulation (rTMS) over the premotor cortex on training-related improvements in motor performance and associated neural plasticity.
Occlusion of the middle cerebral artery is the most common cause of stroke. Because the middle cerebral artery supplies blood to the motor cortices, middle cerebral artery stroke often impacts the integrity of the motor cortex and its associated corticospinal projections. Consequently, the majority of the 6.8 million people who have suffered a stroke in the United States experience hemiparesis as a result of the infarct. Although stroke survivors are encouraged to participate in rehabilitation programs, less than half of all individuals post-stroke regain complete motor function. Because motor deficits, especially of the upper extremities, can dampen the quality of life, there is an urgent need to improve current rehabilitation programs to allow more stroke survivors to achieve higher functional gains.
Motor training is an important part of recovery after stroke. During motor training, stroke patients practice performing a movement and become better at performing the trained movement over time. Repetitive transcranial magnetic stimulation (rTMS), which uses magnetism to excite neurons near the surface of the brain, may further improve performance. Healthy adults made larger training-related improvements in their motor performance when they received rTMS over the primary motor cortex during motor training. There is evidence that the premotor cortex may be a more effective target than the primary motor cortex for rTMS for some stroke survivors. In the current study, the investigator will determine the effect of rTMS over the premotor cortex on training-related improvements in motor performance in healthy adults.
In this study the researchers will evaluate the effect of premotor cortex (PMC) rTMS on motor learning with a double-blind randomized study consisting of five experiments separated by at least 72 hours. During each experiment, participants complete motor training while receiving one of five rTMS protocols. All participants will receive each rTMS protocol once. The order of the rTMS protocols will be randomized and counterbalanced prior to recruitment. The researchers will evaluate the effect of each rTMS protocol on training-related motor learning by collecting kinematic and neurophysiological measurements before (pre-training), immediately post-training, and 60 minutes post-training.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Healthy, right-handed participants complete five testing sessions. During each testing session, participants complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Participants receive a different rTMS protocol at each testing session so that they receive all rTMS protocols by the end of the study.
Device: rTMS Over Contralateral Hemisphere of Premotor Cortex · Device: rTMS Over Ipsilateral Hemisphere of Premotor Cortex · Device: Control 1: rTMS Timed 400 ms After Movement-related EMG · Device: Control 2: rTMS Over the Somatosensory Cortex · Device: Control 3: Sham rTMS · Other: Motor Training
This intervention uses rTMS located over the premotor cortex of the contralateral hemisphere (opposite side of the body) to the training wrist. For this intervention the rTMS occurs at a frequency of 0.1 Hz, 50 milliseconds (ms) before the onset of movement-related electromyography (EMG). The MagStim Super Rapid 2 Transcranial Magnetic Stimulator is used.
Also known as: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
This intervention uses rTMS located over the premotor cortex of the ipsilateral hemisphere (the same side of the body) to the training wrist. For this intervention the rTMS occurs at a frequency of 0.1 Hz, 50 milliseconds (ms) before the onset of movement-related EMG. The MagStim Super Rapid 2 Transcranial Magnetic Stimulator is used.
Also known as: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
Control condition 1 uses rTMS over the premotor cortex of the contralateral hemisphere to the training wrist, with a frequency of 0.1 Hz. The rTMS occurs 400 milliseconds (ms) after the onset of movement-related EMG and uses the MagStim Super Rapid 2 Transcranial Magnetic Stimulator.
Also known as: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
This intervention uses rTMS located over the somatosensory cortex of the contralateral hemisphere to the training wrist. For this intervention the rTMS occurs at a frequency of 0.1 Hz, 50 milliseconds (ms) before the onset of movement-related EMG. The MagStim Super Rapid 2 Transcranial Magnetic Stimulator is used.
Also known as: MagStim Super Rapid 2 Transcranial Magnetic Stimulator
Control condition 3 uses rTMS located over the premotor cortex of the contralateral hemisphere to the training wrist, at a frequency of 0.1 Hz, 50 milliseconds (ms) before the onset of movement-related EMG. The MagStim Super Rapid 2 Transcranial Magnetic Stimulator with the sham coil is used.
Also known as: MagStim Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil
During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
Change in Primary Motor Cortex (M1) Excitability Derived From Stimulus Response Curve (SRC)
Functional organization of ipsilateral M1 is assessed by changes in area under the curve of stimulus response curves over the hotspots of an agonist (extensor carpi ulnaris (ECU)) muscle of the training movement. The area under the curve (AUC) was calculated by summing the mean motor evoked potential (MEP) amplitudes per intensity and subject evoked by TMS at intensities 25 -80% maximum stimulator output (MSO), in increments of 5% MSO. The area under the stimulus response curve is normalized to the pre-training measurement.
Time frame: Baseline/Pre-training, Immediately Post-training, 60 Minutes Post-training during each of 5 study visits (up to 217 days)
Change in Mean Reaction Time
Participants are asked to perform 7 auditory-cued ballistic wrist extensions before and after motor training. Electromyographic (EMG) activity recorded during the ballistic wrist extensions is used to measure reaction time. Reaction time is the length of time between the auditory cue and the onset of the movement-related EMG burst of the extensor carpi ulnaris (ECU) muscle. The change in reaction time from baseline is calculated as the post-training score minus the baseline score.
Time frame: Baseline/Pre-training, Immediately Post-training, 60 Minutes Post-training during each of 5 study visits (up to 217 days)
Change in Mean Peak Velocity
Peak velocity of wrist movement from 6 auditory-paced ballistic wrist extension was collected using a gyrometer. Peak velocity is an assessment of hand motor kinematics. Velocity measures speed in a particular direction of motion.
Time frame: Baseline/Pre-training, Immediately Post-training, 60 Minutes Post-training during each of 5 study visits (up to 217 days)
Participant enrollment began July 7, 2016 and all study visits were completed by November 10, 2019. Participants were enrolled at Emory University in Atlanta, Georgia, USA. The study was suspended for several years and was ultimately terminated in 2024.
| Milestone | Repetitive TMS During Motor Training |
|---|---|
| Started | 11 |
| Rtms over contralateral hemisphere of premotor cortex | 11 |
| Rtms over ipsilateral hemisphere of premotor cortex | 11 |
| Control 1: rtms timed 400 ms after movement-related emg | 11 |
| Control 2: rtms over the somatosensory cortex | 11 |
| Control 3: sham rtms | 11 |
| Completed | 11 |
| Not completed | 0 |
Functional organization of ipsilateral M1 is assessed by changes in area under the curve of stimulus response curves over the hotspots of an agonist (extensor carpi ulnaris (ECU)) muscle of the training movement. The area under the curve (AUC) was calculated by summing the mean motor evoked potential (MEP) amplitudes per intensity and subject evoked by TMS at intensities 25 -80% maximum stimulator output (MSO), in increments of 5% MSO. The area under the stimulus response curve is normalized to the pre-training measurement.
| ratio of pre/post MEP amplitudes | rTMS Over the Premotor Cortex of the Contralateral Hemisphere | rTMS Over the Premotor Cortex of the Ipsilateral Hemisphere | Control 1: rTMS Over the Premotor Cortex of the Contralateral Hemisphere +400ms | Control 2: rTMS Over the Somatosensory Cortex of the Contralateral Hemisphere | Control 3: Sham rTMS |
|---|---|---|---|---|---|
| Baseline to Immediately post-training | 0.50 ± 0.9 | 0.4 ± 0.6 | 0.30 ± 0.55 | 0.35 ± 0.60 | 0.30 ± 0.50 |
| Baseline to 60 minutes post-training | 0.6 ± 1.2 | 0.7 ± 0.9 | 0.8 ± 0.75 | 0.2 ± 0.5 | 0.35 ± 0.36 |
Participants are asked to perform 7 auditory-cued ballistic wrist extensions before and after motor training. Electromyographic (EMG) activity recorded during the ballistic wrist extensions is used to measure reaction time. Reaction time is the length of time between the auditory cue and the onset of the movement-related EMG burst of the extensor carpi ulnaris (ECU) muscle. The change in reaction time from baseline is calculated as the post-training score minus the baseline score.
| milliseconds | rTMS Over the Premotor Cortex of the Contralateral Hemisphere | rTMS Over the Premotor Cortex of the Ipsilateral Hemisphere | Control 1: rTMS Over the Premotor Cortex of the Contralateral Hemisphere +400ms | Control 2: rTMS Over the Somatosensory Cortex of the Contralateral Hemisphere | Control 3: Sham rTMS |
|---|---|---|---|---|---|
| Immediately post-training minus pre-training | -33 (-70 to 2) | -18 (-40 to 8) | 13 (-10 to 36) | -21 (-40 to 6) | -29 (-30 to 5) |
| 60 minutes post-training minus pre-training | -40 (-80 to 0) | -9 (-39 to 20) | -2 (-25 to 21) | -20 (-61 to 21) | -24 (-52 to 4) |
Peak velocity of wrist movement from 6 auditory-paced ballistic wrist extension was collected using a gyrometer. Peak velocity is an assessment of hand motor kinematics. Velocity measures speed in a particular direction of motion.
| degrees per millisecond | rTMS Over the Premotor Cortex of the Contralateral Hemisphere | rTMS Over the Premotor Cortex of the Ipsilateral Hemisphere | Control 1: rTMS Over the Premotor Cortex of the Contralateral Hemisphere +400ms | Control 2: rTMS Over the Somatosensory Cortex of the Contralateral Hemisphere | Control 3: Sham rTMS |
|---|---|---|---|---|---|
| Immediately post-training - Pre-training | 29 (-12.5 to 75) | 10 (-20 to 54) | -13 (-77 to 49) | 90 (50 to 188) | -28 (-88 to 29) |
| 60 minutes post-training - Pre-training | -20 (-76 to 38) | -80 (-125 to 12) | -25 (-95 to 49) | 24 (-20 to 68) | -6 (-77 to 68) |
Collected over Information on adverse events was collected during the each rTMS session, beginning at the first study visit and ending after the fifth study visit (up to 217 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rTMS Over the Premotor Cortex of the Contralateral Hemisphere | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| rTMS Over the Premotor Cortex of the Ipsilateral Hemisphere | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Control 1: rTMS Over the Premotor Cortex of the Contralateral Hemisphere +400ms | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Control 2: rTMS Over the Somatosensory Cortex of the Contralateral Hemisphere | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Control 3: Sham rTMS | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
The Baseline Analysis Population includes participants who contributed data to the analysis of the outcome measures. One participant was not included in data analyses due to technical reasons that caused the data to be unusable.
| Age, Continuous(years) | Repetitive TMS During Motor Training |
|---|---|
| Mean | 56.00 ± 5.73 |
| Sex: Female, Male(Participants) | Repetitive TMS During Motor Training |
|---|---|
| Female | 6 |
| Male | 4 |
| Race and Ethnicity Not Collected(Participants) | Repetitive TMS During Motor Training |
|---|
| Region of Enrollment(Participants) | Repetitive TMS During Motor Training |
|---|---|
| United States | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2016 to primary completion in Nov 2019, 40 months.
Results were first posted in Oct 2026, 6 years 11 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Sep 2015 → Jul 2016, primary completion Feb 2024 → Nov 2019 and completion Feb 2024 → Nov 2019.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study was suspended pending additional funding to continue participant recruitment and was ultimately terminated in 2024.
Study was suspended pending additional funding to continue participant recruitment and was ultimately terminated in 2024.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.